Jove
Visualize
Contact Us

Related Experiment Videos

Secondary Pulmonary Hypertension.

Ronald J. Oudiz1

  • 1Division of Cardiology, Research & Education Institute, Harbor UCLA Medical Center, 1124 West Carson Street, #405, Torrance, CA 90502, USA. oudiz@humc.edu

Current Treatment Options in Cardiovascular Medicine
|March 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Diagnosing pulmonary hypertension requires clinical suspicion due to nonspecific symptoms. Classification guides targeted therapy, with new agents improving treatment for pulmonary arterial hypertension and specific secondary causes.

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Pulmonary hypertension (PH) diagnosis relies on clinical suspicion due to nonspecific symptoms.
  • Accurate classification of PH is crucial for effective patient management and symptom control.
  • Therapies historically focused on supportive care, but novel agents are emerging.

Purpose of the Study:

  • To review current diagnostic and classification approaches for pulmonary hypertension.
  • To discuss therapeutic strategies targeting different categories of PH.
  • To highlight advancements in pharmacological treatments for pulmonary arterial hypertension.

Main Methods:

  • Literature review of diagnostic criteria and classification systems for PH.
  • Analysis of treatment modalities for various PH classifications, including primary and secondary forms.

Related Experiment Videos

  • Examination of novel therapeutic agents and their clinical applications.

    • Main Results:

    • Newer agents offer targeted therapies for pulmonary vasculopathy in pulmonary arterial hypertension.
    • Treatment for secondary PH varies, focusing on underlying causes like left-sided heart disease or pulmonary veno-occlusive disease.
    • Pulmonary vasodilators may be harmful in hypoxemia-related PH but show promise for chronic thromboembolic disease.

    Conclusions:

    • Effective management of pulmonary hypertension necessitates precise classification and targeted therapies.
    • Advancements in pharmacotherapy are transforming treatment paradigms for pulmonary arterial hypertension.
    • Personalized treatment strategies are essential, considering the diverse etiologies and pathophysiologies of PH.